WEST CHESTER, Pennsylvania & ISTANBUL, Turkey
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced that it has entered into an agreement with Molecular Targeting Technologies Inc. (MTTI), a clinical-stage biotechnology company specializing in the development of innovative therapies for rare cancers, an agreement on the delivery of the medical radioisotope “carrier arm (nca, non carrier added) 177Lu “(nca 177Lu) has completed.
Eczacıbaşı-Monrol entered the theranostics market in 2019 as one of the few manufacturers of Lutetium-177 worldwide and has since ensured an uninterrupted supply of this important product to patients in many countries. In line with the company’s mission to improve the quality of life for cancer patients around the world, the company is entering into strategic alliances with international pharmaceutical companies and building a new production facility that meets the FDA’s 21 CFR Part 211 quality standards and an annual capacity of 60,000 cans. Thanks to the location of the new plant near the transport hub of Istanbul, it will benefit from a worldwide logistics network and agreements with freight service providers for transport to 320 destinations around the world.
Aydin Küçük, General Manager von Eczacıbaşı-Monrol, in the center, dass nca177Lu contributes to the company’s mission to add value to people’s lives with leading, innovative approaches to diagnosing and treating critical diseases. He added: “To support our growth in this area, we are building a new GMP certified facility exclusively for the research, development and production of theranostics with a new technology that will enable us to expand our range of high quality lutetium to maximize. Sustainability and innovation are two of our core values. We strive to continuously improve our processes and products. At the same time, we strive to care for patients all over the world. ”
Chris Pak, CEO of Molecular Targeting Technologies Inc. (MTTI), commented: “We have achieved on-time, sustainable supply of an important therapeutic agent that is necessary for the development and launch of our flagship product 177Lu-EBTATE and other EB platform technologies is required. We look forward to the beginning
this cooperation and on establishing a good relationship with a reliable, trustworthy radioisotope supplier such as Eczacıbaşı-Monrol for the supply of nca177To build up Lu. ”
Über Molecular Targeting Technologies Inc. (MTTI)
Molecular Targeting Technologies Inc. is a fast-growing, privately held clinical-stage biotechnology company developing targeted radiotherapeutic and diagnostic agents for rare cancers. We strive to create value by acquiring and deploying innovative imaging, radiopharmaceutical, and theranostic resources to improve people’s health, reduce healthcare costs, and act for the benefit of stakeholders. MTTI is expected to conduct multiple clinical studies in 2022. Additional Information: www.mtarget.com, www.evathera.com
Über Eczacıbaşı-Monrol
Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in the field of nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and offers customer-oriented service worldwide.
Monrol exports high quality, wide range nuclear medicine products to more than 50 countries around the world and has manufacturing facilities and operational projects in various regions. For more information, see www.monrol.com
The source language in which the original text is published is the official and authorized version. Translations will be included for a better understanding. Only the language version that was originally published is legally valid. You should therefore compare the translations with the original language version of the publication.
View original version on businesswire.com: https://www.businesswire.com/news/home/20211124006264/de/
MTTI
Chris, sir
President and CEO
Email: [email protected]
Eczacıbaşı Monrol
Aydin Kucuk
General Manager
Email: [email protected]
© Business Wire, Inc.
Usage notice
This material is not an editorial by AFP. AFP is not responsible for the accuracy of the content. If you have any questions about the content of this communication, please contact the contact person named in the text.
–
